PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Market Cap	$68.89M	P/E Ratio	N/A
52W High	$1.84	52W Low	$0.81
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	49.5%
Overall Score	39	Value Score	60
Quality Score	--	Technical Score	18

EPS Current Est	$-1.54	EPS Next Est	$-1.39
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PMVP	$1.32	+0.76%	166.22K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PMVP	$1.32	+0.8%	166.22K
3
4
5
6

PMVP

PMVP

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get PMV Pharmaceuticals Inc. Data in Excel

Get PMV Pharmaceuticals Inc. Data in Excel